Risk evaluation for the development of cervical intraepithelial neoplasia: Development and validation of risk‐scoring schemes
Cervical cancer screening guidelines do not comprehensively define what constitutes high risk. This study developed and validated simple risk‐scoring schemes to improve Papanicolaou smear screening for women at high risk. Four cumulative risk score (CRS) schemes were derived respectively for the dev...
Gespeichert in:
Veröffentlicht in: | International journal of cancer 2015-01, Vol.136 (2), p.340-349 |
---|---|
Hauptverfasser: | , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 349 |
---|---|
container_issue | 2 |
container_start_page | 340 |
container_title | International journal of cancer |
container_volume | 136 |
creator | Lee, Chien‐Hung Peng, Chiung‐Yu Li, Ruei‐Nian Chen, Yu‐Chieh Tsai, Hsiu‐Ting Hung, Yu‐Hsiu Chan, Te‐Fu Huang, Hsiao‐Ling Lai, Tai‐Cheng Wu, Ming‐Tsang |
description | Cervical cancer screening guidelines do not comprehensively define what constitutes high risk. This study developed and validated simple risk‐scoring schemes to improve Papanicolaou smear screening for women at high risk. Four cumulative risk score (CRS) schemes were derived respectively for the development of cervical intraepithelial neoplasia grade 1 (CIN1) and grade 2 or worse (CIN2+) using community‐based case‐control data (n = 1523). By calculating the area under the receiver operating characteristic (AU‐ROC) curve, these schemes were validated in a Papanicolaou smear follow‐up cohort (n = 967) and a hospital‐based cytology screening population (n = 217). A high DNA load of high‐risk human papillomavirus (HR‐HPV) was the main predictor for CIN1 and CIN2+, although age, married status combined with the number of sexual partners, active and passive smoking and age at sexual debut also affected associated lesions. In the training set, only the HPV‐testing‐contained CIN2+ CRS scheme presented an excellent discrimination for identifying CIN2+ (AU‐ROC = 0.866). Using a CRS cutoff value of 4 to identify CIN2+, the sensitivity and specificity of predicting CIN2+ for the 3‐ and 5‐year follow‐ups were 100% and 90.8%, and 83.3% and 90.4%, respectively, in the validation cohort. In the hospital‐based validation population, the CRS scheme showed comparable discrimination for CIN2+ detection (sensitivity 88.2% and specificity 84.6%). Women with CRS ≥4 had a 5.4% and 9.1% of 3‐ and 5‐year cumulative incidence, respectively, and a 40.5‐fold hazard ratio of developing CIN2+. In conclusion, combined with HR‐HPV testing and verified risk factors, a simple CRS scheme could effectively improve the implementation of CIN2+ screening.
What's new?
Cervical cancer is linked to various risk factors, including persistent infection with strains of high‐risk human papillomavirus (HR‐HPV). However, whether specific risk factor combinations place some women at greater risk than others is unclear. To find out, the authors of this study combined HR‐HPV testing and verified risk factors to develop a cumulative risk score (CRS) scheme. Elevated HR‐HPV DNA load was the primary predictor for cervical intraepithelial neoplasia grade 1 (CIN1) and grade 2 (CIN2), but other factors, such as marital status and smoking, also influenced risk‐scoring. The CRS scheme was especially useful for CIN2+ screening. |
doi_str_mv | 10.1002/ijc.28982 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_1619314729</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1619314729</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4242-cd0045cb51a5e17f8f3d14f0fa2b0aa7427f26ed422ee203c737df0c19007fef3</originalsourceid><addsrcrecordid>eNpdkc1uEzEQxy1ERUPhwAsgS1y4bDPj9ca73FCANlWkSgjOK8c7pg7eD-zdoJ7gEfqMfZK6TahQTx5rfvOfjz9jbxBOEUDM3dacirIqxTM2Q6hUBgKL52yWcpApzBfH7GWMWwDEAuQLdixkKbEqqxn789XFn5x22k96dH3HbR_4eEW8oR35fmipG3lvuaGwc0Z77roxaBpcYrxL_476wevo9Af-6b8S3TU8ibpmr5oUQmp0-_cmmj647geP5opaiq_YkdU-0uvDe8K-f_n8bXmerS_PVsuP68xIIUVmGgBZmE2BuiBUtrR5g9KC1WIDWisplBULaqQQRAJyo3LVWDBYAShLNj9h7_e6Q-h_TRTHunXRkPc6LTDFGhdY5SiVqBL67gm67afQpenuKVXlSiIk6u2BmjYtNfUQXKvDdf3vtAmY74HfztP1Yx6hvvesTp7VD57Vq4vlQ5DfAeQUi80</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1617937410</pqid></control><display><type>article</type><title>Risk evaluation for the development of cervical intraepithelial neoplasia: Development and validation of risk‐scoring schemes</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Lee, Chien‐Hung ; Peng, Chiung‐Yu ; Li, Ruei‐Nian ; Chen, Yu‐Chieh ; Tsai, Hsiu‐Ting ; Hung, Yu‐Hsiu ; Chan, Te‐Fu ; Huang, Hsiao‐Ling ; Lai, Tai‐Cheng ; Wu, Ming‐Tsang</creator><creatorcontrib>Lee, Chien‐Hung ; Peng, Chiung‐Yu ; Li, Ruei‐Nian ; Chen, Yu‐Chieh ; Tsai, Hsiu‐Ting ; Hung, Yu‐Hsiu ; Chan, Te‐Fu ; Huang, Hsiao‐Ling ; Lai, Tai‐Cheng ; Wu, Ming‐Tsang</creatorcontrib><description>Cervical cancer screening guidelines do not comprehensively define what constitutes high risk. This study developed and validated simple risk‐scoring schemes to improve Papanicolaou smear screening for women at high risk. Four cumulative risk score (CRS) schemes were derived respectively for the development of cervical intraepithelial neoplasia grade 1 (CIN1) and grade 2 or worse (CIN2+) using community‐based case‐control data (n = 1523). By calculating the area under the receiver operating characteristic (AU‐ROC) curve, these schemes were validated in a Papanicolaou smear follow‐up cohort (n = 967) and a hospital‐based cytology screening population (n = 217). A high DNA load of high‐risk human papillomavirus (HR‐HPV) was the main predictor for CIN1 and CIN2+, although age, married status combined with the number of sexual partners, active and passive smoking and age at sexual debut also affected associated lesions. In the training set, only the HPV‐testing‐contained CIN2+ CRS scheme presented an excellent discrimination for identifying CIN2+ (AU‐ROC = 0.866). Using a CRS cutoff value of 4 to identify CIN2+, the sensitivity and specificity of predicting CIN2+ for the 3‐ and 5‐year follow‐ups were 100% and 90.8%, and 83.3% and 90.4%, respectively, in the validation cohort. In the hospital‐based validation population, the CRS scheme showed comparable discrimination for CIN2+ detection (sensitivity 88.2% and specificity 84.6%). Women with CRS ≥4 had a 5.4% and 9.1% of 3‐ and 5‐year cumulative incidence, respectively, and a 40.5‐fold hazard ratio of developing CIN2+. In conclusion, combined with HR‐HPV testing and verified risk factors, a simple CRS scheme could effectively improve the implementation of CIN2+ screening.
What's new?
Cervical cancer is linked to various risk factors, including persistent infection with strains of high‐risk human papillomavirus (HR‐HPV). However, whether specific risk factor combinations place some women at greater risk than others is unclear. To find out, the authors of this study combined HR‐HPV testing and verified risk factors to develop a cumulative risk score (CRS) scheme. Elevated HR‐HPV DNA load was the primary predictor for cervical intraepithelial neoplasia grade 1 (CIN1) and grade 2 (CIN2), but other factors, such as marital status and smoking, also influenced risk‐scoring. The CRS scheme was especially useful for CIN2+ screening.</description><identifier>ISSN: 0020-7136</identifier><identifier>EISSN: 1097-0215</identifier><identifier>DOI: 10.1002/ijc.28982</identifier><identifier>PMID: 24841989</identifier><language>eng</language><publisher>United States: Wiley Subscription Services, Inc</publisher><subject>Adult ; Aged ; Cancer ; Case-Control Studies ; Cervical cancer ; cervical cancer screening ; cervical intraepithelial neoplasia ; Cervical Intraepithelial Neoplasia - epidemiology ; Cervical Intraepithelial Neoplasia - pathology ; Cervical Intraepithelial Neoplasia - virology ; Cohort Studies ; DNA, Viral - genetics ; Early Detection of Cancer ; Female ; Follow-Up Studies ; Human papillomavirus ; Humans ; Medical research ; Medical screening ; Middle Aged ; Models, Statistical ; Neoplasm Staging ; Papanicolaou Test ; Papillomaviridae - genetics ; Papillomaviridae - isolation & purification ; Papillomavirus Infections - complications ; Papillomavirus Infections - epidemiology ; Papillomavirus Infections - virology ; Polymerase Chain Reaction ; Prognosis ; Risk Assessment ; risk evaluation ; risk‐scoring scheme ; ROC Curve ; Taiwan - epidemiology ; Uterine Cervical Dysplasia - epidemiology ; Uterine Cervical Dysplasia - pathology ; Uterine Cervical Dysplasia - virology ; Uterine Cervical Neoplasms - epidemiology ; Uterine Cervical Neoplasms - pathology ; Uterine Cervical Neoplasms - virology ; Young Adult</subject><ispartof>International journal of cancer, 2015-01, Vol.136 (2), p.340-349</ispartof><rights>2014 UICC</rights><rights>2014 UICC.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4242-cd0045cb51a5e17f8f3d14f0fa2b0aa7427f26ed422ee203c737df0c19007fef3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fijc.28982$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fijc.28982$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,777,781,1412,27905,27906,45555,45556</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24841989$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lee, Chien‐Hung</creatorcontrib><creatorcontrib>Peng, Chiung‐Yu</creatorcontrib><creatorcontrib>Li, Ruei‐Nian</creatorcontrib><creatorcontrib>Chen, Yu‐Chieh</creatorcontrib><creatorcontrib>Tsai, Hsiu‐Ting</creatorcontrib><creatorcontrib>Hung, Yu‐Hsiu</creatorcontrib><creatorcontrib>Chan, Te‐Fu</creatorcontrib><creatorcontrib>Huang, Hsiao‐Ling</creatorcontrib><creatorcontrib>Lai, Tai‐Cheng</creatorcontrib><creatorcontrib>Wu, Ming‐Tsang</creatorcontrib><title>Risk evaluation for the development of cervical intraepithelial neoplasia: Development and validation of risk‐scoring schemes</title><title>International journal of cancer</title><addtitle>Int J Cancer</addtitle><description>Cervical cancer screening guidelines do not comprehensively define what constitutes high risk. This study developed and validated simple risk‐scoring schemes to improve Papanicolaou smear screening for women at high risk. Four cumulative risk score (CRS) schemes were derived respectively for the development of cervical intraepithelial neoplasia grade 1 (CIN1) and grade 2 or worse (CIN2+) using community‐based case‐control data (n = 1523). By calculating the area under the receiver operating characteristic (AU‐ROC) curve, these schemes were validated in a Papanicolaou smear follow‐up cohort (n = 967) and a hospital‐based cytology screening population (n = 217). A high DNA load of high‐risk human papillomavirus (HR‐HPV) was the main predictor for CIN1 and CIN2+, although age, married status combined with the number of sexual partners, active and passive smoking and age at sexual debut also affected associated lesions. In the training set, only the HPV‐testing‐contained CIN2+ CRS scheme presented an excellent discrimination for identifying CIN2+ (AU‐ROC = 0.866). Using a CRS cutoff value of 4 to identify CIN2+, the sensitivity and specificity of predicting CIN2+ for the 3‐ and 5‐year follow‐ups were 100% and 90.8%, and 83.3% and 90.4%, respectively, in the validation cohort. In the hospital‐based validation population, the CRS scheme showed comparable discrimination for CIN2+ detection (sensitivity 88.2% and specificity 84.6%). Women with CRS ≥4 had a 5.4% and 9.1% of 3‐ and 5‐year cumulative incidence, respectively, and a 40.5‐fold hazard ratio of developing CIN2+. In conclusion, combined with HR‐HPV testing and verified risk factors, a simple CRS scheme could effectively improve the implementation of CIN2+ screening.
What's new?
Cervical cancer is linked to various risk factors, including persistent infection with strains of high‐risk human papillomavirus (HR‐HPV). However, whether specific risk factor combinations place some women at greater risk than others is unclear. To find out, the authors of this study combined HR‐HPV testing and verified risk factors to develop a cumulative risk score (CRS) scheme. Elevated HR‐HPV DNA load was the primary predictor for cervical intraepithelial neoplasia grade 1 (CIN1) and grade 2 (CIN2), but other factors, such as marital status and smoking, also influenced risk‐scoring. The CRS scheme was especially useful for CIN2+ screening.</description><subject>Adult</subject><subject>Aged</subject><subject>Cancer</subject><subject>Case-Control Studies</subject><subject>Cervical cancer</subject><subject>cervical cancer screening</subject><subject>cervical intraepithelial neoplasia</subject><subject>Cervical Intraepithelial Neoplasia - epidemiology</subject><subject>Cervical Intraepithelial Neoplasia - pathology</subject><subject>Cervical Intraepithelial Neoplasia - virology</subject><subject>Cohort Studies</subject><subject>DNA, Viral - genetics</subject><subject>Early Detection of Cancer</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Human papillomavirus</subject><subject>Humans</subject><subject>Medical research</subject><subject>Medical screening</subject><subject>Middle Aged</subject><subject>Models, Statistical</subject><subject>Neoplasm Staging</subject><subject>Papanicolaou Test</subject><subject>Papillomaviridae - genetics</subject><subject>Papillomaviridae - isolation & purification</subject><subject>Papillomavirus Infections - complications</subject><subject>Papillomavirus Infections - epidemiology</subject><subject>Papillomavirus Infections - virology</subject><subject>Polymerase Chain Reaction</subject><subject>Prognosis</subject><subject>Risk Assessment</subject><subject>risk evaluation</subject><subject>risk‐scoring scheme</subject><subject>ROC Curve</subject><subject>Taiwan - epidemiology</subject><subject>Uterine Cervical Dysplasia - epidemiology</subject><subject>Uterine Cervical Dysplasia - pathology</subject><subject>Uterine Cervical Dysplasia - virology</subject><subject>Uterine Cervical Neoplasms - epidemiology</subject><subject>Uterine Cervical Neoplasms - pathology</subject><subject>Uterine Cervical Neoplasms - virology</subject><subject>Young Adult</subject><issn>0020-7136</issn><issn>1097-0215</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdkc1uEzEQxy1ERUPhwAsgS1y4bDPj9ca73FCANlWkSgjOK8c7pg7eD-zdoJ7gEfqMfZK6TahQTx5rfvOfjz9jbxBOEUDM3dacirIqxTM2Q6hUBgKL52yWcpApzBfH7GWMWwDEAuQLdixkKbEqqxn789XFn5x22k96dH3HbR_4eEW8oR35fmipG3lvuaGwc0Z77roxaBpcYrxL_476wevo9Af-6b8S3TU8ibpmr5oUQmp0-_cmmj647geP5opaiq_YkdU-0uvDe8K-f_n8bXmerS_PVsuP68xIIUVmGgBZmE2BuiBUtrR5g9KC1WIDWisplBULaqQQRAJyo3LVWDBYAShLNj9h7_e6Q-h_TRTHunXRkPc6LTDFGhdY5SiVqBL67gm67afQpenuKVXlSiIk6u2BmjYtNfUQXKvDdf3vtAmY74HfztP1Yx6hvvesTp7VD57Vq4vlQ5DfAeQUi80</recordid><startdate>20150115</startdate><enddate>20150115</enddate><creator>Lee, Chien‐Hung</creator><creator>Peng, Chiung‐Yu</creator><creator>Li, Ruei‐Nian</creator><creator>Chen, Yu‐Chieh</creator><creator>Tsai, Hsiu‐Ting</creator><creator>Hung, Yu‐Hsiu</creator><creator>Chan, Te‐Fu</creator><creator>Huang, Hsiao‐Ling</creator><creator>Lai, Tai‐Cheng</creator><creator>Wu, Ming‐Tsang</creator><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7T5</scope><scope>7TO</scope><scope>7U9</scope><scope>H94</scope><scope>K9.</scope><scope>7X8</scope></search><sort><creationdate>20150115</creationdate><title>Risk evaluation for the development of cervical intraepithelial neoplasia: Development and validation of risk‐scoring schemes</title><author>Lee, Chien‐Hung ; Peng, Chiung‐Yu ; Li, Ruei‐Nian ; Chen, Yu‐Chieh ; Tsai, Hsiu‐Ting ; Hung, Yu‐Hsiu ; Chan, Te‐Fu ; Huang, Hsiao‐Ling ; Lai, Tai‐Cheng ; Wu, Ming‐Tsang</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4242-cd0045cb51a5e17f8f3d14f0fa2b0aa7427f26ed422ee203c737df0c19007fef3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Cancer</topic><topic>Case-Control Studies</topic><topic>Cervical cancer</topic><topic>cervical cancer screening</topic><topic>cervical intraepithelial neoplasia</topic><topic>Cervical Intraepithelial Neoplasia - epidemiology</topic><topic>Cervical Intraepithelial Neoplasia - pathology</topic><topic>Cervical Intraepithelial Neoplasia - virology</topic><topic>Cohort Studies</topic><topic>DNA, Viral - genetics</topic><topic>Early Detection of Cancer</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Human papillomavirus</topic><topic>Humans</topic><topic>Medical research</topic><topic>Medical screening</topic><topic>Middle Aged</topic><topic>Models, Statistical</topic><topic>Neoplasm Staging</topic><topic>Papanicolaou Test</topic><topic>Papillomaviridae - genetics</topic><topic>Papillomaviridae - isolation & purification</topic><topic>Papillomavirus Infections - complications</topic><topic>Papillomavirus Infections - epidemiology</topic><topic>Papillomavirus Infections - virology</topic><topic>Polymerase Chain Reaction</topic><topic>Prognosis</topic><topic>Risk Assessment</topic><topic>risk evaluation</topic><topic>risk‐scoring scheme</topic><topic>ROC Curve</topic><topic>Taiwan - epidemiology</topic><topic>Uterine Cervical Dysplasia - epidemiology</topic><topic>Uterine Cervical Dysplasia - pathology</topic><topic>Uterine Cervical Dysplasia - virology</topic><topic>Uterine Cervical Neoplasms - epidemiology</topic><topic>Uterine Cervical Neoplasms - pathology</topic><topic>Uterine Cervical Neoplasms - virology</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lee, Chien‐Hung</creatorcontrib><creatorcontrib>Peng, Chiung‐Yu</creatorcontrib><creatorcontrib>Li, Ruei‐Nian</creatorcontrib><creatorcontrib>Chen, Yu‐Chieh</creatorcontrib><creatorcontrib>Tsai, Hsiu‐Ting</creatorcontrib><creatorcontrib>Hung, Yu‐Hsiu</creatorcontrib><creatorcontrib>Chan, Te‐Fu</creatorcontrib><creatorcontrib>Huang, Hsiao‐Ling</creatorcontrib><creatorcontrib>Lai, Tai‐Cheng</creatorcontrib><creatorcontrib>Wu, Ming‐Tsang</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>Immunology Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>International journal of cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lee, Chien‐Hung</au><au>Peng, Chiung‐Yu</au><au>Li, Ruei‐Nian</au><au>Chen, Yu‐Chieh</au><au>Tsai, Hsiu‐Ting</au><au>Hung, Yu‐Hsiu</au><au>Chan, Te‐Fu</au><au>Huang, Hsiao‐Ling</au><au>Lai, Tai‐Cheng</au><au>Wu, Ming‐Tsang</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Risk evaluation for the development of cervical intraepithelial neoplasia: Development and validation of risk‐scoring schemes</atitle><jtitle>International journal of cancer</jtitle><addtitle>Int J Cancer</addtitle><date>2015-01-15</date><risdate>2015</risdate><volume>136</volume><issue>2</issue><spage>340</spage><epage>349</epage><pages>340-349</pages><issn>0020-7136</issn><eissn>1097-0215</eissn><abstract>Cervical cancer screening guidelines do not comprehensively define what constitutes high risk. This study developed and validated simple risk‐scoring schemes to improve Papanicolaou smear screening for women at high risk. Four cumulative risk score (CRS) schemes were derived respectively for the development of cervical intraepithelial neoplasia grade 1 (CIN1) and grade 2 or worse (CIN2+) using community‐based case‐control data (n = 1523). By calculating the area under the receiver operating characteristic (AU‐ROC) curve, these schemes were validated in a Papanicolaou smear follow‐up cohort (n = 967) and a hospital‐based cytology screening population (n = 217). A high DNA load of high‐risk human papillomavirus (HR‐HPV) was the main predictor for CIN1 and CIN2+, although age, married status combined with the number of sexual partners, active and passive smoking and age at sexual debut also affected associated lesions. In the training set, only the HPV‐testing‐contained CIN2+ CRS scheme presented an excellent discrimination for identifying CIN2+ (AU‐ROC = 0.866). Using a CRS cutoff value of 4 to identify CIN2+, the sensitivity and specificity of predicting CIN2+ for the 3‐ and 5‐year follow‐ups were 100% and 90.8%, and 83.3% and 90.4%, respectively, in the validation cohort. In the hospital‐based validation population, the CRS scheme showed comparable discrimination for CIN2+ detection (sensitivity 88.2% and specificity 84.6%). Women with CRS ≥4 had a 5.4% and 9.1% of 3‐ and 5‐year cumulative incidence, respectively, and a 40.5‐fold hazard ratio of developing CIN2+. In conclusion, combined with HR‐HPV testing and verified risk factors, a simple CRS scheme could effectively improve the implementation of CIN2+ screening.
What's new?
Cervical cancer is linked to various risk factors, including persistent infection with strains of high‐risk human papillomavirus (HR‐HPV). However, whether specific risk factor combinations place some women at greater risk than others is unclear. To find out, the authors of this study combined HR‐HPV testing and verified risk factors to develop a cumulative risk score (CRS) scheme. Elevated HR‐HPV DNA load was the primary predictor for cervical intraepithelial neoplasia grade 1 (CIN1) and grade 2 (CIN2), but other factors, such as marital status and smoking, also influenced risk‐scoring. The CRS scheme was especially useful for CIN2+ screening.</abstract><cop>United States</cop><pub>Wiley Subscription Services, Inc</pub><pmid>24841989</pmid><doi>10.1002/ijc.28982</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0020-7136 |
ispartof | International journal of cancer, 2015-01, Vol.136 (2), p.340-349 |
issn | 0020-7136 1097-0215 |
language | eng |
recordid | cdi_proquest_miscellaneous_1619314729 |
source | MEDLINE; Wiley Online Library Journals Frontfile Complete; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
subjects | Adult Aged Cancer Case-Control Studies Cervical cancer cervical cancer screening cervical intraepithelial neoplasia Cervical Intraepithelial Neoplasia - epidemiology Cervical Intraepithelial Neoplasia - pathology Cervical Intraepithelial Neoplasia - virology Cohort Studies DNA, Viral - genetics Early Detection of Cancer Female Follow-Up Studies Human papillomavirus Humans Medical research Medical screening Middle Aged Models, Statistical Neoplasm Staging Papanicolaou Test Papillomaviridae - genetics Papillomaviridae - isolation & purification Papillomavirus Infections - complications Papillomavirus Infections - epidemiology Papillomavirus Infections - virology Polymerase Chain Reaction Prognosis Risk Assessment risk evaluation risk‐scoring scheme ROC Curve Taiwan - epidemiology Uterine Cervical Dysplasia - epidemiology Uterine Cervical Dysplasia - pathology Uterine Cervical Dysplasia - virology Uterine Cervical Neoplasms - epidemiology Uterine Cervical Neoplasms - pathology Uterine Cervical Neoplasms - virology Young Adult |
title | Risk evaluation for the development of cervical intraepithelial neoplasia: Development and validation of risk‐scoring schemes |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-18T08%3A05%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Risk%20evaluation%20for%20the%20development%20of%20cervical%20intraepithelial%20neoplasia:%20Development%20and%20validation%20of%20risk%E2%80%90scoring%20schemes&rft.jtitle=International%20journal%20of%20cancer&rft.au=Lee,%20Chien%E2%80%90Hung&rft.date=2015-01-15&rft.volume=136&rft.issue=2&rft.spage=340&rft.epage=349&rft.pages=340-349&rft.issn=0020-7136&rft.eissn=1097-0215&rft_id=info:doi/10.1002/ijc.28982&rft_dat=%3Cproquest_pubme%3E1619314729%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1617937410&rft_id=info:pmid/24841989&rfr_iscdi=true |